Dr Cosimo De Nunzio speaks to ecancer about the preliminary results of the MITOBCG study evaluating the safety of sequential Mitomycin and Bacillus Calmette-Guérin treatment versus Bacillus Calmette-Guérin monotherapy in patients with high-risk non-muscle invasive bladder cancer.

He talks about BCG being one of the standard treatments offered to patients with high-risk bladder cancer and the fact that many of them are resistant to it.

He then discusses the methodology of the study, which is currently still ongoing, and talks about how patients were randomised into two treatment groups.

Finally, he discusses how the results from this study could impact the future treatment of high-risk non-muscle invasive bladder cancer by providing an alternative to BCG and potentially reducing the risk of recurrence in high-risk patients. He underlines that the preliminary results indicate a lack of major adverse events associated with the proposed treatment.